Jason Gardner
2022 - Dianthus Therapeutics
In 2022, Jason Gardner earned a total compensation of $1.7M as Former President and Chief Executive Officer at Dianthus Therapeutics, a 26% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $326,288 |
|---|---|
| Option Awards | $756,413 |
| Salary | $565,000 |
| Other | $7,147 |
| Total | $1,654,848 |
Gardner received $756.4K in option awards, accounting for 46% of the total pay in 2022.
Gardner also received $326.3K in non-equity incentive plan, $565K in salary and $7.1K in other compensation.
Rankings
In 2022, Jason Gardner's compensation ranked 2,057th out of 5,753 executives tracked by ExecPay. In other words, Gardner earned more than 64.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 2,057 out of 5,753 | 64th |
Division Manufacturing | 1,108 out of 3,133 | 65th |
Major group Chemicals And Allied Products | 476 out of 1,419 | 67th |
Industry group Drugs | 437 out of 1,320 | 67th |
Industry Pharmaceutical Preparations | 319 out of 966 | 67th |
Source: SEC filing on April 11, 2024.
Gardner's colleagues
We found two more compensation records of executives who worked with Jason Gardner at Dianthus Therapeutics in 2022.
News
Dianthus Therapeutics Former President, Chief Financial and Operating Officer Stephen Mahoney's 2023 pay jumps 48% to $1.7M
April 11, 2024
Dianthus Therapeutics CEO Jason Gardner's 2021 pay falls 28% to $2.2M
May 2, 2022
Marqeta CEO Jason Gardner's 2021 pay jumps 7,132% to $224M
April 25, 2022
Dianthus Therapeutics CEO Jason Gardner's 2020 pay jumps 88% to $3.1M
April 21, 2021
Dianthus Therapeutics CEO Jason Gardner's 2018 pay jumps 692% to $4.7M
April 25, 2019